tiprankstipranks
InMed’s Study Highlights Cannabinol’s Potential in Skincare
Company Announcements

InMed’s Study Highlights Cannabinol’s Potential in Skincare

Story Highlights

InMed Pharmaceuticals (INM) has released an update.

Pick the best stocks and maximize your portfolio:

InMed Pharmaceuticals has published a promising study showcasing the anti-inflammatory effects of cannabinol (CBN) on skin diseases, highlighting its potential for therapeutic and cosmetic applications. This research emphasizes CBN’s ability to modulate the endocannabinoid system and regulate inflammation in conditions such as psoriasis and dermatitis. The findings could pave the way for new treatments targeting inflammation in various diseases.

For further insights into INM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskInMed Pharmaceuticals’ 2024 AGM Results Announced
TipRanks Canadian Auto-Generated NewsdeskInMed Pharmaceuticals Secures $10 Million Equity Purchase Agreement
TipRanks Auto-Generated NewsdeskInMed Pharmaceuticals Explores CBN for Skin Disease Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App